Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Sep 2012
Randomized Controlled Trial Multicenter StudyRandomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres (Creon 40000 MMS) in patients with pancreatic exocrine insufficiency due to chronic pancreatitis--a double-blind, placebo-controlled study.
Pancreatic exocrine insufficiency (PEI) results in maldigestion, leading to abdominal pain, steatorrhoea, malnutrition and weight loss. ⋯ The results provide evidence for the efficacy of pancreatin (Creon 40000 MMS) in patients with pancreatic exocrine insufficiency due to chronic pancreatitis, and confirm that this formulation is well tolerated, with a good safety profile, at the dose administered.
-
Aliment. Pharmacol. Ther. · Sep 2012
Multicenter StudyAdmission time is associated with outcome of upper gastrointestinal bleeding: results of a multicentre prospective cohort study.
It has been suggested that patients presenting with upper gastrointestinal bleeding (UGIB) during the weekend have a worse outcome compared with weekdays, with an increased risk of recurrent bleeding and mortality. ⋯ Although quality of care did not appear to differ between week/weekend admissions, patients with suspected upper gastrointestinal bleeding admitted during the weekend were at higher risk of an adverse outcome. This might be due to the fact that these patients have more severe haemorrhage.
-
Aliment. Pharmacol. Ther. · Sep 2012
Case ReportsMesenteric phlebosclerosis associated with long-term oral intake of geniposide, an ingredient of herbal medicine.
Idiopathic mesenteric phlebosclerosis (IMP) is a rare disease, characterised by thickening of the wall of the right hemicolon with calcification of mesenteric veins. However, the aetiology remains unknown. ⋯ The long-term use of geniposide in herbal medicines appears to be associated with mesenteric phlebosclerosis.
-
Aliment. Pharmacol. Ther. · Sep 2012
Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients.
Ulcerative colitis (UC) and Crohn's disease can sometimes relapse and be refractory to standard treatment following orthotopic liver transplantation (OLT) despite post-transplantation immunosuppressive therapy. ⋯ Starting Anti-TNF therapy following orthotopic liver transplantation appears to be a potential option for inflammatory bowel disease management. Additional studies are needed, however, to confirm these findings and to further assess risks associated with this treatment strategy.